Guy Boeckxstaens

List of Publications by Year
in descending order

121 papers	10,794 citations	44069 48 h-index	31849 101 g-index
127 all docs	127 docs citations	127 times ranked	9788 citing authors

#	Article	IF	Citations
1	Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunology, 2005, 6, 844-851.	14.5	1,009
2	Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia. New England Journal of Medicine, 2011, 364, 1807-1816.	27.0	780
3	Achalasia. Lancet, The, 2014, 383, 83-93.	13.7	470
4	Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut, 2014, 63, 1293-1299.	12.1	429
5	Outcomes of Treatment for Achalasia Depend on Manometric Subtype. Gastroenterology, 2013, 144, 718-725.	1.3	387
6	Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. Cell, 2018, 175, 400-415.e13.	28.9	371
7	A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut, 2014, 63, 938-948.	12.1	332
8	The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010, 59, 1213-1221.	12.1	328
9	Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut, 2016, 65, 732-739.	12.1	321
10	Histamine Receptor H1â€"Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology, 2016, 150, 875-887.e9.	1.3	263
11	The cellular composition of the human immune system is shaped by age and cohabitation. Nature Immunology, 2016, 17, 461-468.	14.5	258
12	Efficacy of Treatment for Patients With Achalasia Depends on the Distensibility of the Esophagogastric Junction. Gastroenterology, 2012, 143, 328-335.	1.3	256
13	Symptomatic reflux disease: the present, the past and the future. Gut, 2014, 63, 1185-1193.	12.1	226
14	The Vagus Nerve in Appetite Regulation, Mood, and IntestinalÂInflammation. Gastroenterology, 2017, 152, 730-744.	1.3	221
15	Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung. Nature Communications, 2019, 10, 3964.	12.8	206
16	Activation of the Cholinergic Anti-Inflammatory Pathway Ameliorates Postoperative Ileus in Mice. Gastroenterology, 2007, 133, 1219-1228.	1.3	202
17	The Spectrum of Achalasia: Lessons From Studies of Pathophysiology andÂHigh-Resolution Manometry. Gastroenterology, 2013, 145, 954-965.	1.3	180
18	Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute. Clinical Gastroenterology and Hepatology, 2017, 15, 325-334.	4.4	177

#	Article	IF	Citations
19	The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut, 2010, 59, 441-451.	12.1	166
20	Local immune response to food antigens drives meal-induced abdominal pain. Nature, 2021, 590, 151-156.	27.8	153
21	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut, 2017, 66, 411-420.	12.1	137
22	Incidence of prolonged postoperative ileus after colorectal surgery: a systematic review and metaâ€analysis. Colorectal Disease, 2016, 18, O1-9.	1.4	131
23	Effect of adrenergic and nitrergic blockade on experimental ileus in rats. British Journal of Pharmacology, 1997, 120, 464-468.	5.4	128
24	Management of achalasia: surgery or pneumatic dilation. Gut, 2011, 60, 869-876.	12.1	125
25	Vagus Nerve Activity Augments Intestinal Macrophage Phagocytosis via Nicotinic Acetylcholine Receptor Î±4Î²2. Gastroenterology, 2009, 137, 1029-1039.e4.	1.3	119
26	Faster Recovery of Gastrointestinal Transit After Laparoscopy and Fast-Track Care in Patients Undergoing Colonic Surgery. Gastroenterology, 2011, 141, 872-880.e4.	1.3	117
27	Dietary and pharmacological treatment of abdominal pain in IBS. Gut, 2017, 66, 966-974.	12.1	115
28	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nature Genetics, 2014, 46, 901-904.	21.4	104
29	Fundamentals of Neurogastroenterology: Physiology/Motility â€" Sensation. Gastroenterology, 2016, 150, 1292-1304.e2.	1.3	103
30	Effects of Lesogaberan on Reflux and Lower Esophageal Sphincter Function in Patients With Gastroesophageal Reflux Disease. Gastroenterology, 2010, 139, 409-417.	1.3	100
31	Achalasia: Virus-Induced Euthanasia of Neurons. American Journal of Gastroenterology, 2008, 103, 1610-1612.	0.4	99
32	Neuro-Anatomical Evidence Indicating Indirect Modulation of Macrophages by Vagal Efferents in the Intestine but Not in the Spleen. PLoS ONE, 2014, 9, e87785.	2.5	95
33	New therapeutic strategies for postoperative ileus. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 675-683.	17.8	84
34	Sensitivity Testing in Irritable Bowel Syndrome With Rectal Capsaicin Stimulations: Role of TRPV1 Upregulation and Sensitization in Visceral Hypersensitivity?. American Journal of Gastroenterology, 2014, 109, 99-109.	0.4	81
35	CCR2-dependent monocyte-derived macrophages resolve inflammation and restore gut motility in postoperative ileus. Gut, 2017, 66, 2098-2109.	12.1	78
36	Relevance of mast cellâ€"nerve interactions in intestinal nociception. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 74-84.	3.8	77

#	Article	IF	Citations
37	Mucosal Immune Cell Numbers and Visceral Sensitivity in Patients With Irritable Bowel Syndrome: Is There Any Relationship?. American Journal of Gastroenterology, 2012, 107, 715-726.	0.4	77
38	Selective Î±7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. British Journal of Pharmacology, 2010, 160, 322-333.	5.4	74
39	Muscularis macrophages: Key players in intestinal homeostasis and disease. Cellular Immunology, 2018, 330, 142-150.	3.0	72
40	Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut, 2016, 65, 1279-1288.	12.1	71
41	A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut, 2011, 60, 1182-1188.	12.1	70
42	Conservative Management of Esophageal Perforations During Pneumatic Dilation for Idiopathic Esophageal Achalasia. Clinical Gastroenterology and Hepatology, 2012, 10, 142-149.	4.4	69
43	Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. Gut, 2019, 68, 1406-1416.	12.1	69
44	Mast cells and inflammatory bowel disease. Current Opinion in Pharmacology, 2015, 25, 45-49.	3.5	65
45	Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity. American Journal of Physiology - Renal Physiology, 2017, 312, G635-G648.	3.4	62
46	The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease. Frontiers in Immunology, 2015, 6, 590.	4.8	59
47	Current Diagnosis and Management of Achalasia. Journal of Clinical Gastroenterology, 2014, 48, 484-490.	2.2	56
48	Intestinal resident macrophages: Multitaskers of the gut. Neurogastroenterology and Motility, 2020, 32, e13843.	3.0	53
49	British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring. Gut, 2019, 68, 1731-1750.	12.1	52
50	Niche-specific functional heterogeneity of intestinal resident macrophages. Gut, 2021, 70, 1383-1395.	12.1	52
51	Genetic variants in<i>CDC42</i>and<i>NXPH1</i>as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	12.1	49
52	Role of VIP1/PACAP receptors in postoperative ileus in rats. British Journal of Pharmacology, 1998, 124, 1181-1186.	5.4	48
53	Intestinal macrophages and their interaction with the enteric nervous system in health and inflammatory bowel disease. Acta Physiologica, 2019, 225, e13163.	3.8	47
54	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Scientific Reports, 2017, 7, 14680.	3.3	46

#	Article	IF	Citations
55	Comparison between the cervical and abdominal vagus nerves in mice, pigs, and humans. Neurogastroenterology and Motility, 2020, 32, e13889.	3.0	44
56	Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS. Gut, 2021, 70, 1275-1286.	12.1	44
57	Abnormal distribution of the interstitial cells of Cajal in an adult patient with pseudo-obstruction and megaduodenum. American Journal of Gastroenterology, 2002, 97, 2120-2126.	0.4	43
58	Functional characterization of oxazolone-induced colitis and survival improvement by vagus nerve stimulation. PLoS ONE, 2018, 13, e0197487.	2.5	42
59	Vagotomy Affects the Development of Oral Tolerance and Increases Susceptibility to Develop Colitis Independently of Î±-7 Nicotinic Receptor. Molecular Medicine, 2016, 22, 464-476.	4.4	41
60	Will Reflux Kill POEM?. Endoscopy, 2017, 49, 625-628.	1.8	39
61	Neuron-macrophage crosstalk in the intestine: a â€œmicrogliaâ€• perspective. Frontiers in Cellular Neuroscience, 2015, 9, 403.	3.7	37
62	Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Alimentary Pharmacology and Therapeutics, 2019, 49, 723-732.	3.7	37
63	Stress-Induced Visceral Hypersensitivity in Maternally Separated Rats Can Be Reversed by Peripherally Restricted Histamine-1-Receptor Antagonists. PLoS ONE, 2013, 8, e66884.	2.5	37
64	Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity. Experimental Physiology, 2014, 99, 1299-1311.	2.0	36
65	Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. Cell Reports, 2018, 25, 798-810.e6.	6.4	36
66	Intestinal neuro-immune interactions: focus on macrophages, mast cells and innate lymphoid cells. Current Opinion in Neurobiology, 2020, 62, 68-75.	4.2	36
67	Nicotine Attenuates Activation of Tissue Resident Macrophages in the Mouse Stomach through the Î²2 Nicotinic Acetylcholine Receptor. PLoS ONE, 2013, 8, e79264.	2.5	35
68	Proton Pump Inhibitors Reduce the Size and Acidity of the Acid Pocket in the Stomach. Clinical Gastroenterology and Hepatology, 2014, 12, 1101-1107.e1.	4.4	35
69	A metaâ€analysis of immunogenetic Caseâ€"Control Association Studies in irritable bowel syndrome. Neurogastroenterology and Motility, 2015, 27, 717-727.	3.0	35
70	Pathophysiology of Gastroesophageal Reflux Disease. Gastroenterology Clinics of North America, 2014, 43, 15-25.	2.2	32
71	Splenic autonomic denervation increases inflammatory status but does not aggravate atherosclerotic lesion development. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H646-H654.	3.2	32
72	Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS ONE, 2018, 13, e0193943.	2.5	32

#	Article	IF	Citations
73	Vagal innervation is required for the formation of tertiary lymphoid tissue in colitis. European Journal of Immunology, 2016, 46, 2467-2480.	2.9	31
74	Achalasia and esophagoâ€gastric junction outflow obstruction: focus on the subtypes. Neurogastroenterology and Motility, 2012, 24, 27-31.	3.0	30
75	Preoperative risk factors for prolonged postoperative ileus after colorectal resection. International Journal of Colorectal Disease, 2017, 32, 883-890.	2.2	30
76	Neuroimmune interaction and the regulation of intestinal immune homeostasis. American Journal of Physiology - Renal Physiology, 2018, 314, G75-G80.	3.4	30
77	Vagus nerve stimulation dampens intestinal inflammation in a murine model of experimental food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1748-1759.	5.7	29
78	Immune activation in irritable bowel syndrome: what is the evidence?. Nature Reviews Immunology, 2022, 22, 674-686.	22.7	29
79	Mast Cells Play No Role in the Pathogenesis of Postoperative Ileus Induced by Intestinal Manipulation. PLoS ONE, 2014, 9, e85304.	2.5	28
80	Alterations confined to the gastro-oesophageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 821-829.	2.4	27
81	The clinical importance of the anti-inflammatory vagovagal reflex. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 119-134.	1.8	27
82	Achalasia: From New Insights in Pathophysiology to Treatment. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, S36-S37.	1.8	24
83	Management of Achalasia. Gastroenterology Clinics of North America, 2013, 42, 45-55.	2.2	23
84	Reflux inhibitors: a new approach for GERD?. Current Opinion in Pharmacology, 2008, 8, 685-689.	3.5	22
85	IBS and the role of otilonium bromide. International Journal of Colorectal Disease, 2013, 28, 295-304.	2.2	22
86	Translational gastrointestinal pharmacology in the 21st century: â€˜the lesogaberan storyâ€™. Current Opinion in Pharmacology, 2011, 11, 630-633.	3.5	20
87	Expression of immuneâ€related genes in rectum and colon <i>descendens</i> of Irritable Bowel Syndrome patients is unrelated to clinical symptoms. Neurogastroenterology and Motility, 2019, 31, e13579.	3.0	16
88	Ephrinâ€B2 signaling in the spinal cord as a player in postâ€inflammatory and stressâ€induced visceral hypersensitivity. Neurogastroenterology and Motility, 2020, 32, e13782.	3.0	14
89	Republished: Symptomatic reflux disease: the present, the past and the future. Postgraduate Medical Journal, 2015, 91, 46-54.	1.8	13
90	Finding the Right Treatment for Achalasia Treatment: Risks, Efficacy, Complications. Current Treatment Options in Gastroenterology, 2016, 14, 420-428.	0.8	13

#	Article	IF	Citations
91	Screening for Dysplasia With Lugol Chromoendoscopy in Longstanding Idiopathic Achalasia. American Journal of Gastroenterology, 2018, 113, 855-862.	0.4	12
92	Pneumatic balloon dilatation versus laparoscopic Heller myotomy for achalasia: a failed attempt at meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 602-611.	2.4	12
93	Vagus Nerve Stimulation Promotes Epithelial Proliferation and Controls Colon Monocyte Infiltration During DSS-Induced Colitis. Frontiers in Medicine, 2021, 8, 694268.	2.6	12
94	Dietary Marine nâ€“3 PUFAs Do Not Affect Stress-Induced Visceral Hypersensitivity in a Rat Maternal Separation Model1â€“3. Journal of Nutrition, 2015, 145, 915-922.	2.9	11
95	Irritable bowel syndrome: focus on otilonium bromide. Expert Review of Gastroenterology and Hepatology, 2014, 8, 131-137.	3.0	10
96	Measuring Mechanical Properties of the Esophageal Wall Using Impedance Planimetry. Gastrointestinal Endoscopy Clinics of North America, 2014, 24, 607-618.	1.4	10
97	Economic evaluation of the randomized European Achalasia trial comparing pneumodilation with Laparoscopic Heller myotomy. Neurogastroenterology and Motility, 2017, 29, e13115.	3.0	10
98	Revisiting Epidemiologic Features of Achalasia. Clinical Gastroenterology and Hepatology, 2017, 15, 374-375.	4.4	10
99	The Emerging Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterology and Hepatology, 2018, 14, 250-252.	0.1	8
100	Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR. American Journal of Gastroenterology, 2017, 112, 1888-1889.	0.4	7
101	Bioelectronics in the brainâ€“gut axis: focus on inflammatory bowel disease (IBD). International Immunology, 2021, 33, 337-348.	4.0	7
102	The Spleen Responds to Intestinal Manipulation but Does Not Participate in the Inflammatory Response in a Mouse Model of Postoperative Ileus. PLoS ONE, 2014, 9, e102211.	2.5	6
103	Muscularis macrophages: trained guardians of enteric neurons. Cell Research, 2022, 32, 229-230.	12.0	6
104	Nitric Oxide Release in Response to Stimulation of Nonadrenergic, Noncholinergic Nerves. Journal of Cardiovascular Pharmacology, 1991, 17, S238-S242.	1.9	5
105	Achalasia: From Bench to Peroral Endoscopic Myotomy. Digestive Diseases, 2016, 34, 476-482.	1.9	5
106	24â€hour multiâ€pH recording of the postprandial acid pocket and the nocturnal acid distribution at the esophagogastric junction in healthy volunteers. Neurogastroenterology and Motility, 2019, 31, e13694.	3.0	5
107	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. Journal of Cellular and Molecular Medicine, 2021, 25, 8047-8061.	3.6	5
108	Pathophysiology, diagnosis, and treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology, 1996, 12, 365-372.	2.3	4

#	Article	IF	Citations
109	245 Evidence for a New Mechanism Underlying Persistent Visceral Hypersensitivity and Increased Permeability in a Model of Post-Infectious IBS. Gastroenterology, 2015, 148, S-55.	1.3	4
110	Local immune response as novel disease mechanism underlying abdominal pain in patients with irritable bowel syndrome. Acta Clinica Belgica, 2022, 77, 889-896.	1.2	4
111	No association between the common calcium-sensing receptor polymorphism rs1801725 and irritable bowel syndrome. BMC Medical Genetics, 2015, 16, 110.	2.1	3
112	Prospective study evaluating immuneâ€mediated mechanisms and predisposing factors underlying persistent postinfectious abdominal complaints. Neurogastroenterology and Motility, 2019, 31, e13542.	3.0	3
113	Inhibition of Serine Proteases as a Novel Therapeutic Strategy for Abdominal Pain in IBS. Frontiers in Physiology, 2022, 13, .	2.8	3
114	Food Antigen-Specific Antibodies and Mast Cell Activation in Post-Infectious Visceral Hypersensitivity. Gastroenterology, 2017, 152, S721.	1.3	1
115	1092 - Food Antigen-Specific Sensitization of Nociceptive Nerves as an Underlying Mechanism of Visceral Pain in Ibs. Gastroenterology, 2018, 154, S-214-S-215.	1.3	1
116	Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?. Current Opinion in Pharmacology, 2008, 8, 669-670.	3.5	0
117	Response to Drs Trang and Graham. American Journal of Gastroenterology, 2014, 109, 137.	0.4	0
118	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1314-1315.	4.4	0
119	A18 DIETARY ANTIGEN RE-CHALLENGE INCREASES NOCICEPTIVE NEURON EXCITABILITY IN A POST-INFECTIOUS IBS MODEL.. Journal of the Canadian Association of Gastroenterology, 2018, 1, 29-30.	0.3	0
120	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission â€" confounded by the gut microbiome? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1088-1089.	3.7	0
121	Shining light on the neuro-immune axis in the gut. Immunity, 2021, 54, 850-852.	14.3	0